The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma.
Kathrine T IsaksenKlaus BeiskeErlend B SmelandJudit JørgensenMarianne BrodtkorbJune Helen MyklebustMats JerkemanLeo MerirantaMarja-Liisa Karjalainen-LindsbergSirpa LeppäDavid W ScottHarald HolteYngvild Nuvin BlakerPublished in: EJHaem (2020)
Keyphrases
- diffuse large b cell lymphoma
- clinical trial
- phase ii
- gene expression
- epstein barr virus
- end stage renal disease
- open label
- newly diagnosed
- ejection fraction
- dna methylation
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- genome wide
- randomized controlled trial
- high throughput
- phase iii
- double blind
- patient reported
- placebo controlled
- single cell